Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
Dizhe Pharmaceuticals: Two core products in the company's hematologic oncology pipeline have a total of 9 latest research findings selected for the 2026 European Hematology Association Annual Meeting
Dizhe Pharmaceutical announced that two of the company’s two major core products in its blood oncology pipeline—Gohreze and birelentinib—have a total of 9 latest research findings selected for the 2026 European Hematology Association (EHA) Annual Meeting. The conference will be held in Stockholm, Sweden, from June 11 to 14. Gohreze has 8 selected research findings, covering monotherapy and combination treatment regimens for PTCL in the first-line setting and the relapsed/refractory (r/r) stages, including exploration in rare PTCL subtypes.